KPV, a peptide (three linked protein building blocks) cut from a natural hormone, is offered for gut and skin inflammation. It calms inflammation in laboratory dishes and rodents but has never been tested in a human trial. Most product is sold outside pharmacy oversight, and self-treating bowel symptoms can delay diagnosis of serious disease. For health-focused adults targeting long-lasting inflammation, it is an experimental, short-course option with unknown long-term risk. (Full Review)

Protocol

Oral (gut-focused) approach

200–500 mcg once or twice daily

Capsules, commonly on an empty stomach; some protocols escalate to 1–2 mg daily. No dose of KPV has been tested in humans.

Subcutaneous (systemic) approach

200–500 mcg once daily

Reconstituted from freeze-dried powder, usually in the morning; no evidence that injection outperforms oral use.

Topical approach

Compounded creams or serums

Unstandardized strength; intact skin blocks passive entry, so effects may depend on damaged or inflamed skin.

Time to effect

Ulcerative colitis (KdPT analog)

2 weeks

Related analog separated from placebo; not KPV itself.

Gut symptoms

1–4 weeks

Peptide-clinic reports; no KPV human data exist.

Benefits

Low: Reduced intestinal inflammation

Speculative: Skin inflammation and pollution protection; wound and corneal healing; antimicrobial activity; neuroprotection after brain injury; airway inflammation; pain reduction; fever reduction; colitis-associated colorectal cancer prevention; lower systemic inflammation; vascular calcification; lower body fat and liver fat

Contraindications

Pregnant or breastfeeding women

People under 18 years of age

Active systemic infection or sepsis

Organ-transplant recipients and others on maintenance immunosuppression

Active cancer or undergoing cancer treatment

Moderate-to-severe active ulcerative colitis (Mayo score ≥6) or active Crohn's disease, using KPV in place of standard therapy

Severe kidney impairment (eGFR <30 mL/min/1.73 m²)

Known hypersensitivity to KPV or product excipients (inactive ingredients)

Competitive athletes

Key Interactions

Immunosuppressants and biologics (methotrexate, tacrolimus, infliximab, adalimumab)

Corticosteroids (prednisone, budesonide)

PepT1-transported drugs (valacyclovir, cephalexin, cefadroxil, enalapril)

NSAIDs (ibuprofen, naproxen, aspirin)

Other research peptides (BPC-157, TB-500, GHK-Cu)

Anti-inflammatory supplements (curcumin, fish-oil omega-3 fatty acids, boswellia)

Vaccination (theoretical)

Risk & Side Effects

Speculative: Contaminated, mislabeled, or non-sterile product; injection-site reactions; antibody or immune reactions to the peptide; blunted immune defense; delayed diagnosis of serious bowel disease; unknown long-term effects

Monitoring

Marker	Target	Why
hs-CRP	<0.5 mg/L	Systemic inflammation
Fecal calprotectin	<50 µg/g	Gut inflammation
White blood cell count (from CBC)	5.0–8.0 × 10⁹/L	Screens for immune suppression or infection
ALT and AST	ALT <25 U/L, AST <25 U/L	Liver safety of an unregulated product
Creatinine and eGFR	eGFR >90 mL/min/1.73 m²	Kidney clearance of peptides

Cadence: Baseline panel before a first course; inflammation markers and safety labs typically repeated at 4 weeks, at the end of each 4–8 week course, then every 6–12 months if courses are repeated.

Qualitative Assessment

Gut symptoms: stool frequency and form (Bristol Stool Scale), bloating, and abdominal pain in a daily diary
Skin: redness, itch, and lesion area, documented with standardized photographs
Joint and muscle comfort: morning stiffness and recovery after exercise
Energy and sleep quality: daily 1–10 ratings
Injection sites: redness, swelling, or lumps

KPV for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment